The benefits and risks of long-term PUVA photochemotherapy
- PMID: 9589196
- DOI: 10.1016/s0733-8635(05)70005-x
The benefits and risks of long-term PUVA photochemotherapy
Abstract
In 1974 a new photobiologic principle i.e. light + drug, called photochemotherapy was discovered in Boston and immediately confirmed in Vienna. Psoralen + UVA (PUVA) photochemotherapy has now been applied to the treatment of more than 24 heterogeneous groups of diseases, especially psoriasis and mycosis fungoides. After 24 years of experience in thousands of patients with psoriasis and 23 other skin disorders, virtually the only risk is the development of squamous-cell carcinomas. This risk is low with two exceptions: previous history of treatment with ionizing radiation or inorganic trivalent arsenic, and patients with recalcitrant psoriasis who require continuous treatment for many years. In a recent report from a large USA clinical trial, melanoma developed in a few patients with psoriasis treated with PUVA. This prospective clinical trial did not have a control population, and therefore, the conclusion that PUVA can cause melanoma is tentative.
Similar articles
-
Nonmelanoma skin tumors in long-term photochemotherapy treatment of psoriasis. An 8-year follow-up study.J Am Acad Dermatol. 1986 Nov;15(5 Pt 1):960-5. doi: 10.1016/s0190-9622(86)70257-0. J Am Acad Dermatol. 1986. PMID: 3782536
-
Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:22-31. doi: 10.1111/j.1468-3083.2012.04520.x. J Eur Acad Dermatol Venereol. 2012. PMID: 22512677 Review.
-
Side-effects of psoralen photochemotherapy (PUVA).Br J Dermatol. 1990 Jun;122 Suppl 36:117-25. doi: 10.1111/j.1365-2133.1990.tb02889.x. Br J Dermatol. 1990. PMID: 2196078 Review.
-
[Photochemotherapy (PUVA): pro and con].Hautarzt. 1985 Jan;36(1):25-33. Hautarzt. 1985. PMID: 3918959 German.
-
Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?Drug Saf. 1999 Apr;20(4):289-97. doi: 10.2165/00002018-199920040-00001. Drug Saf. 1999. PMID: 10230579 Review.
Cited by
-
Targeting and processing of site-specific DNA interstrand crosslinks.Environ Mol Mutagen. 2010 Jul;51(6):527-39. doi: 10.1002/em.20557. Environ Mol Mutagen. 2010. PMID: 20196133 Free PMC article. Review.
-
SNEV(Prp19/PSO4) deficiency increases PUVA-induced senescence in mouse skin.Exp Dermatol. 2016 Mar;25(3):212-7. doi: 10.1111/exd.12910. Exp Dermatol. 2016. PMID: 26663487 Free PMC article.
-
Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand crosslinks, while MSH2 functions in DNA repair.PLoS Genet. 2008 Sep 12;4(9):e1000189. doi: 10.1371/journal.pgen.1000189. PLoS Genet. 2008. PMID: 18787700 Free PMC article.
-
Polyamines alleviate the inhibitory effect of the DNA cross-linking agent mitomycin C on root growth.Plant Signal Behav. 2019;14(11):1659687. doi: 10.1080/15592324.2019.1659687. Epub 2019 Aug 26. Plant Signal Behav. 2019. PMID: 31446839 Free PMC article.
-
Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.Appl Environ Microbiol. 2018 Nov 30;84(24):e01280-18. doi: 10.1128/AEM.01280-18. Print 2018 Dec 15. Appl Environ Microbiol. 2018. PMID: 30389764 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical